US6878728B1
(en)
|
1999-06-11 |
2005-04-12 |
Vertex Pharmaceutical Incorporated |
Inhibitors of aspartyl protease
|
US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
US5614533A
(en)
*
|
1987-03-13 |
1997-03-25 |
Bio-Mega/Boehringer Ingelheim Research, Inc. |
Substituted pipecolinic acid derivatives as HIV protease inhibitors
|
USH1649H
(en)
|
1987-07-31 |
1997-05-06 |
Barrish; Joel C. |
HIV protease inhibitor combinations
|
CA1340588C
(fr)
*
|
1988-06-13 |
1999-06-08 |
Balraj Krishan Handa |
Derive d'aminoacides
|
GB8927915D0
(en)
*
|
1989-12-11 |
1990-02-14 |
Hoffmann La Roche |
Novel alcohols
|
US5430041A
(en)
*
|
1991-05-10 |
1995-07-04 |
Hoffmann-La Roche Inc. |
Amino acid derivatives having antiviral activity
|
CN1071930A
(zh)
*
|
1991-07-10 |
1993-05-12 |
伊莱利利公司 |
用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
|
US5508407A
(en)
*
|
1991-07-10 |
1996-04-16 |
Eli Lilly And Company |
Retroviral protease inhibitors
|
WO1993008184A1
(fr)
*
|
1991-10-23 |
1993-04-29 |
Merck & Co., Inc. |
Inhibiteurs de la protease du vih______________________
|
DK0541168T3
(da)
*
|
1991-11-08 |
1998-05-11 |
Merck & Co Inc |
HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
|
US5413999A
(en)
*
|
1991-11-08 |
1995-05-09 |
Merck & Co., Inc. |
HIV protease inhibitors useful for the treatment of AIDS
|
US6071895A
(en)
|
1992-03-11 |
2000-06-06 |
Narhex Limited |
Polar-substituted hydrocarbons
|
NZ249789A
(en)
|
1992-03-11 |
1997-07-27 |
Narhex Ltd |
Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
|
US5888992A
(en)
|
1992-03-11 |
1999-03-30 |
Narhex Limited |
Polar substituted hydrocarbons
|
EP0560268B1
(fr)
*
|
1992-03-13 |
1995-01-04 |
Bio-Mega/Boehringer Ingelheim Research Inc. |
Dérivés de l'acide pipécolinic comme inhibiteurs de HIV-protéase
|
AU667376B2
(en)
*
|
1992-05-21 |
1996-03-21 |
Monsanto Company |
Retroviral protease inhibitors
|
US5559256A
(en)
*
|
1992-07-20 |
1996-09-24 |
E. R. Squibb & Sons, Inc. |
Aminediol protease inhibitors
|
KR100296463B1
(ko)
|
1992-08-25 |
2001-10-24 |
죤 에이치. 뷰센 |
레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드
|
US5723490A
(en)
*
|
1992-09-08 |
1998-03-03 |
Vertex Pharmaceuticals Incorporated |
THF-containing sulfonamide inhibitors of aspartyl protease
|
IS2334B
(is)
*
|
1992-09-08 |
2008-02-15 |
Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) |
Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
|
US5783701A
(en)
*
|
1992-09-08 |
1998-07-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
TW372972B
(en)
*
|
1992-10-23 |
1999-11-01 |
Novartis Ag |
Antiretroviral acyl compounds
|
US5380849A
(en)
*
|
1992-11-09 |
1995-01-10 |
Merck & Co., Inc. |
Process for optically pure decahydroisoqiunolines
|
US5430150A
(en)
*
|
1992-12-16 |
1995-07-04 |
American Cyanamid Company |
Retroviral protease inhibitors
|
MX9308016A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
|
US5491166A
(en)
*
|
1992-12-22 |
1996-02-13 |
Eli Lilly And Company |
Inhibitors of HIV protease useful for the treatment of AIDS
|
US5434265A
(en)
*
|
1992-12-22 |
1995-07-18 |
Eli Lilly And Company |
Inhibitors of HIV protease
|
US5733906A
(en)
*
|
1993-10-12 |
1998-03-31 |
Eli Lilly And Company |
Inhibitors of HIV Protease useful for the treatment of Aids
|
US5484926A
(en)
*
|
1993-10-07 |
1996-01-16 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
MX9308025A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
|
US5846993A
(en)
*
|
1992-12-22 |
1998-12-08 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
WO1994017096A1
(fr)
*
|
1993-01-17 |
1994-08-04 |
Schering Corporation |
Peptides ayant une activite anti-vih
|
US5939430A
(en)
*
|
1993-02-22 |
1999-08-17 |
Merrell Pharmaceuticals Inc. |
Combinations of retroviral inhibitors
|
US5455353A
(en)
*
|
1993-03-24 |
1995-10-03 |
Hoffmann-La Roche Inc. |
4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
|
ATE149162T1
(de)
*
|
1993-07-15 |
1997-03-15 |
Hoffmann La Roche |
Verfahren zur herstellung eines n- tert.butylisochinolin-3-carboxamid derivates und zwischenprodukte in diesem verfahren
|
HUT74685A
(en)
*
|
1994-02-02 |
1997-01-28 |
Lilly Co Eli |
Hiv protease inhibitors and intermediates piperidine derivatives condensed with heterocycles as intermediates for hiv protease inhibitors
|
CN1146201A
(zh)
*
|
1994-03-07 |
1997-03-26 |
沃泰克斯药物股份有限公司 |
用作天冬氨酰蛋白酶抑制剂的磺胺衍生物
|
US5527829A
(en)
*
|
1994-05-23 |
1996-06-18 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5470979A
(en)
*
|
1994-07-01 |
1995-11-28 |
American Cyanamid Company |
Asymmetric synthesis of bicyclic amino acid esters
|
US5523463A
(en)
*
|
1994-09-23 |
1996-06-04 |
Hoffmann-La Roche Inc. |
Method of producing halogenated and alpha-aminoalchohols
|
US5591885A
(en)
*
|
1994-09-23 |
1997-01-07 |
Hoffman-La Roche Inc. |
Process for the preparation of halogenated α-aminoketone compounds
|
US5691372A
(en)
*
|
1995-04-19 |
1997-11-25 |
Vertex Pharmaceuticals Incorporated |
Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
|
CA2224125C
(fr)
*
|
1995-06-06 |
2004-09-28 |
F. Hoffmann-La Roche Ag |
Compositions pharmaceutiques comprenant un inhibiteur de proteinases et un monoglyceride
|
US6008228A
(en)
*
|
1995-06-06 |
1999-12-28 |
Hoffman-La Roche Inc. |
Pharmaceutical compositions containing proteinase inhibitors
|
US6004957A
(en)
*
|
1995-06-07 |
1999-12-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
AU759386B2
(en)
*
|
1995-06-29 |
2003-04-10 |
Abbvie Inc. |
Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
|
US6037157A
(en)
|
1995-06-29 |
2000-03-14 |
Abbott Laboratories |
Method for improving pharmacokinetics
|
US6270808B1
(en)
|
1995-11-13 |
2001-08-07 |
Gerard Voerman |
Anti-viral isolates obtainable from leeches
|
US5914332A
(en)
*
|
1995-12-13 |
1999-06-22 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
US5883252A
(en)
*
|
1996-01-26 |
1999-03-16 |
Vertex Pharmaceuticals Incorporated |
Aspartyl protease inhibitors
|
US5587481A
(en)
*
|
1996-02-20 |
1996-12-24 |
The Monsanto Company |
Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
|
EP0823424A1
(fr)
*
|
1996-08-09 |
1998-02-11 |
F. Hoffmann-La Roche Ag |
Procédé pour la préparation de quinargine
|
US5914404A
(en)
*
|
1996-08-09 |
1999-06-22 |
Hoffmann-La Roche Inc. |
Process for the preparation of quinargine
|
US5925759A
(en)
|
1996-09-05 |
1999-07-20 |
Agouron Pharmaceuticals, Inc. |
Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
|
US5705647A
(en)
*
|
1996-09-05 |
1998-01-06 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US5962725A
(en)
|
1996-09-05 |
1999-10-05 |
Agouron Pharmaceuticals, Inc. |
Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
|
US6232333B1
(en)
|
1996-11-21 |
2001-05-15 |
Abbott Laboratories |
Pharmaceutical composition
|
DK0847994T3
(da)
|
1996-12-11 |
2003-07-28 |
Hoffmann La Roche |
Fremgangsmåde til fremstilling af blandede anhydrider
|
US6001851A
(en)
*
|
1997-03-13 |
1999-12-14 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US6084107A
(en)
*
|
1997-09-05 |
2000-07-04 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US6143742A
(en)
*
|
1997-12-11 |
2000-11-07 |
Fuisz Technologies Ltd |
Treatment for necrotizing infections
|
US6436989B1
(en)
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
PT1086076E
(pt)
*
|
1998-06-19 |
2005-05-31 |
Vertex Pharma |
Inibidores de sulfonamida de aspartil protease
|
KR100277723B1
(ko)
|
1998-12-14 |
2001-01-15 |
남창우 |
광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
|
US7115584B2
(en)
*
|
1999-01-22 |
2006-10-03 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US7635690B2
(en)
*
|
1999-01-22 |
2009-12-22 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US6765019B1
(en)
|
1999-05-06 |
2004-07-20 |
University Of Kentucky Research Foundation |
Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
|
ES2265946T3
(es)
*
|
1999-06-04 |
2007-03-01 |
Abbott Laboratories |
Formulaciones farmaceuticas mejoradas que contienen ritonavir.
|
US6589962B1
(en)
|
1999-07-20 |
2003-07-08 |
Merck & Co., Inc. |
Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
|
EP1202626A4
(fr)
*
|
1999-07-20 |
2002-10-30 |
Merck & Co Inc |
Derives alpha-hydroxy-gamma-[[(carbocycliques-ou heterocycliques-substitues)amino]carbonyle]alcanamide et utilisations de ceux-ci
|
ATE377011T1
(de)
|
1999-11-24 |
2007-11-15 |
Merck & Co Inc |
Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
|
IT1313682B1
(it)
*
|
1999-11-25 |
2002-09-09 |
Archimica Spa |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
PT1248600E
(pt)
|
2000-01-19 |
2008-08-25 |
Abbott Lab |
Formulações farmacêuticas melhoradas de inibidores da protease do vih
|
WO2001082919A2
(fr)
*
|
2000-05-04 |
2001-11-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Procedes et composes d'inhibition de la calpaine
|
IT1318986B1
(it)
*
|
2000-10-09 |
2003-09-19 |
Archimica S P A Ora Clariant L |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
GB0028483D0
(en)
|
2000-11-22 |
2001-01-10 |
Hoffmann La Roche |
Hydroxyethylamine HIV protease inhibitors
|
US20030191121A1
(en)
*
|
2001-08-09 |
2003-10-09 |
Miller Ross A. |
Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
|
AU2002359721A1
(en)
|
2001-12-19 |
2003-07-09 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
US20040067216A1
(en)
*
|
2002-02-22 |
2004-04-08 |
Karki Shyam B. |
Hiv protease inhibitors supported on cation exchange resins for oral administration
|
CA2477088A1
(fr)
|
2002-02-22 |
2003-10-02 |
New River Pharmaceuticals Inc. |
Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
US7115652B2
(en)
*
|
2002-06-17 |
2006-10-03 |
Sunesis Pharmaceuticals, Inc. |
Aspartyl protease inhibitors
|
EP1515944A1
(fr)
*
|
2002-06-17 |
2005-03-23 |
Sunesis Pharmaceuticals, Inc. |
Inhibiteurs de l'aspartyl-protease
|
KR20070087194A
(ko)
*
|
2003-07-11 |
2007-08-27 |
에프. 호프만-라 로슈 아게 |
사퀴나비르 메실레이트 경구 투여 형태
|
EP1604662A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2
|
SI2258376T1
(sl)
|
2004-07-27 |
2019-04-30 |
Gilead Sciences, Inc. |
Analogi fosfonata spojin inhibitorjev HIV
|
WO2006134612A1
(fr)
*
|
2005-06-16 |
2006-12-21 |
Hetero Drugs Limited |
Procédé de préparation du saquinavir à l’aide d’un nouvel intermédiaire
|
JP5448854B2
(ja)
|
2007-03-12 |
2014-03-19 |
ウェルズ ファーゴ バンク ナショナル アソシエイション |
オリゴマー−プロテアーゼ阻害剤複合体
|
EP2167089A1
(fr)
*
|
2007-06-29 |
2010-03-31 |
Gilead Sciences, Inc. |
Compositions thérapeutiques et leur utilisation
|
TW200914011A
(en)
*
|
2007-06-29 |
2009-04-01 |
Gilead Sciences Inc |
Therapeutic compositions and methods
|
JP2010540517A
(ja)
*
|
2007-09-25 |
2010-12-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hivプロテアーゼ阻害剤
|
WO2009114151A1
(fr)
*
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Conjugués oligomères-acides aminés et oligomères-atazanavir
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EA201692167A1
(ru)
|
2008-12-09 |
2017-07-31 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
US8716262B2
(en)
*
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
MX2011006890A
(es)
*
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
EP2435037B1
(fr)
|
2009-05-27 |
2014-11-12 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
EP2440249A2
(fr)
|
2009-06-12 |
2012-04-18 |
Nektar Therapeutics |
Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique
|
DE102010004957A1
(de)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
CN104017020B
(zh)
|
2010-03-31 |
2017-04-12 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
EP2632895B1
(fr)
|
2010-10-28 |
2018-10-03 |
Merck Canada Inc. |
Inhibiteurs de la protéase du vih
|
EP2392926A1
(fr)
|
2011-02-09 |
2011-12-07 |
Roche Diagnostics GmbH |
Biomarqueurs urinaires chez des sujets infectés par le VIH
|
WO2013059928A1
(fr)
|
2011-10-26 |
2013-05-02 |
Merck Canada Inc. |
Inhibiteurs de la protéase du vih
|
WO2013105118A1
(fr)
|
2012-01-10 |
2013-07-18 |
Council Of Scientific & Industrial Research |
Procédé pour la synthèse d' azido-époxyde synthétique et son utilisation en tant qu'intermédiaire de la synthèse d'amprénavir et de saquinavir
|
KR20150053971A
(ko)
|
2012-09-11 |
2015-05-19 |
머크 샤프 앤드 돔 코포레이션 |
Hiv 프로테아제 억제제
|
EP2912047B1
(fr)
|
2012-10-29 |
2016-08-24 |
Cipla Limited |
Analogues de phosphonate antiviraux et leur procédé de préparation
|
WO2015013835A1
(fr)
|
2013-07-31 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
|
WO2015095276A1
(fr)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
US9737545B2
(en)
|
2013-12-19 |
2017-08-22 |
Merck Sharp & Dohme Corp. |
HIV protease inhibitors
|
WO2015134366A1
(fr)
|
2014-03-06 |
2015-09-11 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la protéase du vih
|
US10138255B2
(en)
|
2014-03-10 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Piperazine derivatives as HIV protease inhibitors
|
WO2016001907A1
(fr)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
|
KR102019572B1
(ko)
|
2014-07-11 |
2019-09-06 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 톨-유사 수용체의 조정제
|
US9738664B2
(en)
|
2014-10-29 |
2017-08-22 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of HIV protease
|
US20180263985A1
(en)
|
2015-09-15 |
2018-09-20 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|